The psychedelic field is entering a new phase. In the early days, most of the conversation was about healing journeys, mystical insights, and the power of guided experiences. Now the focus is shifting. It’s less about big ideas and more about practical details: what the compounds are, how they work, how long they last, and how they can fit into real treatment models.
Three compounds are now leading that shift: MM120, MindMed’s LSD analog; CYB‑003, Helus Pharma’s deuterated psilocybin; and GM2505, Gilgamesh Pharma’s short-acting tryptamine. All three target the serotonin 2A receptor, but each takes a different approach to delivering tighter control over timing, dose, and clinical delivery.
MM120 is currently the most clinically advanced LSD-based compound in development. It has entered Phase 3 trials for generalized anxiety disorder (GAD) and major depressive disorder (MDD). In March 2024, MindMed announced that the FDA had granted Breakthrough Therapy Designation for MM120 in GAD, following positive topline results from its Phase 2b study (MindMed, 2024a). Although detailed efficacy data have not yet been peer-reviewed or publicly disclosed, the company reported "rapid, robust, and durable" symptom reductions. In 2025, MindMed began dosing patients in two pivotal Phase 3 GAD trials—Voyage and Panorama (MindMed, 2025b)—as well as the Emerge Phase 3 trial in MDD, which began dosing in April (MindMed, 2025a). These studies are designed to assess MM120 as a standalone pharmacological treatment, without the structured psychotherapy used in many other psychedelic trials.
CYB‑003 is a deuterated psilocybin analog in Phase 3 development for major depressive disorder (MDD). In March 2024, the FDA granted it Breakthrough Therapy Designation for adjunctive treatment in MDD (Cybin, 2024c). In a Phase 2 study, two 12 mg doses produced a 79% remission rate at six weeks, while longer-term follow-up showed 75% remission at four months in the 16 mg cohort, with an average 22-point reduction in MADRS scores (Cybin, 2024a; Cybin, 2024b). At 12 months, 71% of patients remained in remission, and 100% were classified as responders after two doses of 16 mg (Cybin, 2024a). Cybin has since launched its global PARADIGM Phase 3 program, which includes the APPROACH, EMBRACE, and EXTEND studies. The APPROACH trial is already enrolling across dozens of sites; EMBRACE is expected to begin in the first half of 2025, and EXTEND will follow as an open-label extension. Topline results from APPROACH are projected for 2026 (Cybin, 2024d). While the treatment model retains therapist involvement, CYB‑003’s tighter pharmacokinetics are designed to reduce variability and support broader scalability.
Gilgamesh Pharmaceuticals’ GM2505 is emerging as one of the most innovative compounds in the psychedelic pipeline. In May 2025, the company reported Phase 2a data showing that a single intraveinous dose led to over 90% remission by day 29 in patients with major depressive disorder, including 94% remission in the high-dose cohort (Fierce Biotech, 2025; ClinicalTrialsArena, 2025). The molecule is a synthetic tryptamine designed for rapid onset and short duration—with psychoactive effects lasting only 60 to 90 minutes, compared to several hours for psilocybin (Pharmaphorum, 2024). These pharmacokinetics may support scalable outpatient or even at-home treatment models, assuming continued safety. Phase 1 data confirmed fast absorption and elimination, and the Phase 2a study reported no serious adverse events (PR Newswire, 2023; Fierce Biotech, 2025).
Together, MM120, CYB‑003, and GM2505 show how the field is evolving. These aren’t just substances tied to rituals or guided journeys. They’re being refined as targeted tools: molecules with specific roles in treating mental health. That doesn’t mean therapy and meaning are gone, but it does mean we're entering a new chapter. The focus is on making treatments safe, effective, and accessible at scale.
This isn’t about abandoning past insight—it’s about adapting what worked into models that real systems can support. These three compounds are central to that shift. They're not experiments anymore.
References
- MindMed (2024a). FDA grants Breakthrough Therapy Designation and 12-week Phase 2b data reported: 65% clinical response, 48% remission. Company press release, March 7, 2024.
- MindMed (2025a). First patient dosed in Phase 3 Emerge study of MM120 for MDD. Company press release, April 15, 2025.
- MindMed (2025b). First patient dosed in Panorama Phase 3 study of MM120 for GAD. Company press release, January 30, 2025.
- Cybin (2024a). Phase 2 topline results: 71% remission and 61% MADRS reduction following 16 mg CYB003 dosing. Company press release, March 28, 2024.
- Cybin (2024b). Additional cohort data: 79% remission at 6 weeks following 12 mg dose of CYB003. Company update, January 2024.
- Cybin (2024c). CYB003 receives FDA Breakthrough Therapy Designation. Company press release, March 7, 2024.
- Cybin (2024d). Launch of global PARADIGM Phase 3 program across 18 sites. Company announcement, May 2024.
- Fierce Biotech (2025, May 27). Gilgamesh links psychedelic to 94% remission rate in midphase depression trial. Fierce Biotech.
- ClinicalTrialsArena (2025, May 27). Gilgamesh’s psychedelic touts 94% remission rate in depression study.
- Pharmaphorum (2024, May). AbbVie takes option on Gilgamesh CNS drugs in $2bn deal.
- PR Newswire (2023, Nov 30). Gilgamesh Pharmaceuticals Successfully Completes Phase 1 SAD Clinical Trial of GM‑2505.
